FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4245969404> ?p ?o ?g. }

• W4245969404 abstract "Background and Objective: There is existence of data on the successful application of Eptifibatide, a cyclic heptapeptide inhibitor of glycoprotein IIb/IIIa receptor with its short half-life in coronary interventions. There is minimal literature in the application of stroke treatment. Our objective was to report the results of an open labeled retrospective registry to evaluate the safety (in regards to hemorrhagic complications) and efficacy (regarding discharge NIHSS) of administering high dose IV Eptifibatide as a standalone therapy for acute stroke in patients ineligible for IV r-tPa or neurointervention. Methods: All patients with acute ischemic events between 2010-13 were included that presented to our university affiliated comprehensive stroke center. Patients that received Eptifibatide as standalone therapy were reviewed. Eptifibatide was administered intravenously as a 135-μg/kg single-dose bolus, then a 0.5-μg/kg/min infusion. Charts were reviewed for all patients to assess for primary safety and efficacy endpoint. The primary safety endpoint was bleeding. Bleeding complications were classified as major (symptomatic intracranial hemorrhage and hemoglobin decrease by >5mg/dl), minor (hemoglobin decrease 3-5 mg/dl) and insignificant as proposed by the TIMI score (Thrombolysis in Myocardial Infarction). The primary efficacy end point was neurological improvement/deterioration as defined by a change in discharge NIHSS by > 4 points compared to initial NIHSS respectively. Results: Of a total patient population of 2,329, total of 20 patients (mean age of 73, 50% male (n=10)) received Eptifibatide administered intravenously for a mean duration of 32.5 hours (range 17-67 hours). No major or minor bleeding was observed except for a patient who exhibited minor complication of knee hemarthroses. 9 patients demonstrated early neurological improvement with only 2 exhibiting neurological deterioration related to extension of ischemic core. Conclusion: Application of IV Eptifibatide in achieving recanalization and preventing extension may be a safe standalone therapy in acute ischemic stroke patients ineligible for other neurological interventions. Larger randomized trials are required to corroborate our findings." @default.
• W4245969404 created "2022-05-12" @default.
• W4245969404 creator A5005411055 @default.
• W4245969404 creator A5051619294 @default.
• W4245969404 creator A5060071341 @default.
• W4245969404 creator A5073002957 @default.
• W4245969404 creator A5083072999 @default.
• W4245969404 creator A5083212019 @default.
• W4245969404 creator A5091274355 @default.
• W4245969404 creator A5091594078 @default.
• W4245969404 date "2015-02-01" @default.
• W4245969404 modified "2023-10-16" @default.
• W4245969404 title "Abstract W P61: Safety and <i>E</i> fficacy of <i>I</i> ntravenous <i>E</i> ptifibatide as <i>S</i> tandalone <i>T</i> herapy for select <i>A</i> cute Ischemic Stroke Patients (SIESTA-I trial)" @default.
• W4245969404 doi "https://doi.org/10.1161/str.46.suppl_1.wp61" @default.
• W4245969404 hasPublicationYear "2015" @default.
• W4245969404 type Work @default.
• W4245969404 citedByCount "1" @default.
• W4245969404 countsByYear W42459694042022 @default.
• W4245969404 crossrefType "journal-article" @default.
• W4245969404 hasAuthorship W4245969404A5005411055 @default.
• W4245969404 hasAuthorship W4245969404A5051619294 @default.
• W4245969404 hasAuthorship W4245969404A5060071341 @default.
• W4245969404 hasAuthorship W4245969404A5073002957 @default.
• W4245969404 hasAuthorship W4245969404A5083072999 @default.
• W4245969404 hasAuthorship W4245969404A5083212019 @default.
• W4245969404 hasAuthorship W4245969404A5091274355 @default.
• W4245969404 hasAuthorship W4245969404A5091594078 @default.
• W4245969404 hasConcept C126322002 @default.
• W4245969404 hasConcept C127413603 @default.
• W4245969404 hasConcept C141071460 @default.
• W4245969404 hasConcept C203092338 @default.
• W4245969404 hasConcept C2777995511 @default.
• W4245969404 hasConcept C2779581417 @default.
• W4245969404 hasConcept C2780400711 @default.
• W4245969404 hasConcept C2780645631 @default.
• W4245969404 hasConcept C2781056559 @default.
• W4245969404 hasConcept C42219234 @default.
• W4245969404 hasConcept C43376680 @default.
• W4245969404 hasConcept C500558357 @default.
• W4245969404 hasConcept C535046627 @default.
• W4245969404 hasConcept C71924100 @default.
• W4245969404 hasConcept C78519656 @default.
• W4245969404 hasConceptScore W4245969404C126322002 @default.
• W4245969404 hasConceptScore W4245969404C127413603 @default.
• W4245969404 hasConceptScore W4245969404C141071460 @default.
• W4245969404 hasConceptScore W4245969404C203092338 @default.
• W4245969404 hasConceptScore W4245969404C2777995511 @default.
• W4245969404 hasConceptScore W4245969404C2779581417 @default.
• W4245969404 hasConceptScore W4245969404C2780400711 @default.
• W4245969404 hasConceptScore W4245969404C2780645631 @default.
• W4245969404 hasConceptScore W4245969404C2781056559 @default.
• W4245969404 hasConceptScore W4245969404C42219234 @default.
• W4245969404 hasConceptScore W4245969404C43376680 @default.
• W4245969404 hasConceptScore W4245969404C500558357 @default.
• W4245969404 hasConceptScore W4245969404C535046627 @default.
• W4245969404 hasConceptScore W4245969404C71924100 @default.
• W4245969404 hasConceptScore W4245969404C78519656 @default.
• W4245969404 hasIssue "suppl_1" @default.
• W4245969404 hasLocation W42459694041 @default.
• W4245969404 hasOpenAccess W4245969404 @default.
• W4245969404 hasPrimaryLocation W42459694041 @default.
• W4245969404 hasRelatedWork W1975495438 @default.
• W4245969404 hasRelatedWork W1984774611 @default.
• W4245969404 hasRelatedWork W2047764457 @default.
• W4245969404 hasRelatedWork W2077300746 @default.
• W4245969404 hasRelatedWork W2088249991 @default.
• W4245969404 hasRelatedWork W2090944577 @default.
• W4245969404 hasRelatedWork W2094308415 @default.
• W4245969404 hasRelatedWork W2133326664 @default.
• W4245969404 hasRelatedWork W2350020234 @default.
• W4245969404 hasRelatedWork W2366428215 @default.
• W4245969404 hasVolume "46" @default.
• W4245969404 isParatext "false" @default.
• W4245969404 isRetracted "false" @default.
• W4245969404 workType "article" @default.